Evista is the brand name for the drug raloxifene, an oral selective estrogen receptor modulator. It is used primarily to prevent and treat osteoporosis in postmenopausal women. The medication works by binding to estrogen receptors in bone and breast tissue, acting as an antagonist that reduces bone resorption. At the same time, it exhibits partial agonist activity in the uterus, providing protection without stimulating excessive growth. By altering the conformation of estrogen receptors, raloxifene changes the downstream signaling pathways that regulate bone mineral density and lipid metabolism. This dual action helps maintain bone strength while reducing the risk of invasive breast cancer.

Evista is the brand name for the drug raloxifene, a selective estrogen receptor modulator used mainly for preventing and treating osteoporosis in postmenopausal women. It works by mimicking estrogen in bone tissue to reduce bone loss while blocking estrogen in the breast and uterus. The medication binds to estrogen receptors in bone cells, stabilizing bone remodeling and increasing bone mineral density. By antagonizing estrogen receptors in breast tissue, Evista lowers the risk of invasive breast cancer in women at high risk. Its selective activity provides anti-resorptive effects in bone without stimulating the uterus as estrogen therapy does. Raloxifene is metabolized in the liver and excreted through the bile, giving it a long half-life that supports once daily dosing. Clinical studies show that regular use improves bone density and significantly cuts the incidence of vertebral fractures over several years. The drug is prescribed as an oral tablet that must be taken continuously to maintain its protective effects.

Common side effects often include mild fatigue or headache. Some individuals may experience temporary nausea or dizziness. Skin reactions such as redness or itching can occur in certain users. Gastrointestinal discomfort sometimes appears but usually resolves quickly. Based on reported cases the likelihood of these effects is generally low. Monitoring symptoms and adjusting dosage when needed helps manage these occurrences.

Side effects are generally mild and short lived. Headache is reported frequently among users. Fatigue or drowsiness may occur during the first few days. Dry mouth can develop without serious consequences. Nausea sometimes appears but often resolves quickly. These reactions typically do not require medical intervention. Most people find that symptoms improve as the body adjusts.